1/8 SGLT2 inhibitors are a cornerstone of HF prevention, but do they work in patients with a genetic predisposition to cardiomyopathy? Out in @NatureMedicine, our latest from the @TIMI_Study_Group evaluates dapagliflozin in carriers of rare CMP variants.